SETBP1 and atypical chronic myeloid leukemia, BCR-ABL1 negative: Given their significant impact on disease biology, SETBP1 mutations are now considered a key molecular marker in aCML, and their detection may aid in refining risk stratification and guiding more aggressive treatment approaches, including early consideration of allogeneic stem cell transplantation.